Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclon...
Q1 2026
May 7, 2026
FY 2025
Mar 9, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 14, 2025